Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty
Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it noted uncertainty around the company’s near-term growth prospects despite ...
IBM initiated, Southwest upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...
Zacks.com on MSN2h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?
Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...
thearabianpost5h
Monoclonal Antibodies: A New Era in Alzheimer’s Treatment
Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...
Biogen initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...
STAT6h
How the ‘amyloid mafia’ took over Alzheimer’s research
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Eisai stock price target cut to JPY5,000 at Citi, retains Buy rating
Citi analysts adjusted their outlook on Eisai Co Ltd (OTC:ESAIY). (4523:JP) (OTC: ESALY), reducing the price target from JPY6,000 to JPY5,000, while continuing to endorse the stock with a Buy rating.